Lawrence Friedhoff

4.9k total citations · 3 hit papers
55 papers, 3.9k citations indexed

About

Lawrence Friedhoff is a scholar working on Pharmacology, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Lawrence Friedhoff has authored 55 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pharmacology, 11 papers in Molecular Biology and 9 papers in Psychiatry and Mental health. Recurrent topics in Lawrence Friedhoff's work include Cholinesterase and Neurodegenerative Diseases (9 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Treatment of Major Depression (7 papers). Lawrence Friedhoff is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (9 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Treatment of Major Depression (7 papers). Lawrence Friedhoff collaborates with scholars based in United States, Sweden and Canada. Lawrence Friedhoff's co-authors include Samantha Rogers, Sharon L. Rogers, Martin R. Farlow, Richard C. Mohs, Rachelle S. Doody, Geetha Ramaswamy, Ilise Lombardo, Stephen C. Piscitelli, Jane Hecker and Martin N. Rossor and has published in prestigious journals such as Neurology, Nature Reviews Drug Discovery and Cancer Research.

In The Last Decade

Lawrence Friedhoff

55 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

1998 1.3k citations Samantha Rogers, Lawrence Friedhoff et al. Neurology profile →
The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial

1996 611 citations Sharon L. Rogers, Lawrence Friedhoff Dementia and Geriatric Cognitive Disorders profile →
DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study

2015 583 citations Ilise Lombardo, Geetha Ramaswamy et al. Alzheimer s & Dementia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lawrence Friedhoff United States	18	1.5k	1.5k	1.1k	551	475	55	3.9k
Kimberly Schafer United States	21	1.5k 1.0×	955 0.6×	1.9k 1.7×	641 1.2×	753 1.6×	38	4.7k
Samantha Rogers United Kingdom	18	1.6k 1.0×	1.3k 0.9×	799 0.7×	284 0.5×	417 0.9×	37	3.0k
Shelia Jin United States	16	1.3k 0.8×	907 0.6×	1.5k 1.3×	390 0.7×	608 1.3×	28	3.9k
Albrecht Stöffler Germany	13	965 0.6×	971 0.6×	1.1k 0.9×	614 1.1×	606 1.3×	18	3.3k
Ara S. Khachaturian United States	25	1.4k 0.9×	863 0.6×	1.8k 1.6×	733 1.3×	627 1.3×	51	4.3k
Christopher Ernesto United States	11	1.6k 1.1×	709 0.5×	1.5k 1.4×	466 0.8×	439 0.9×	11	3.6k
Roger Lane United States	42	2.2k 1.4×	2.4k 1.6×	1.3k 1.2×	700 1.3×	603 1.3×	111	6.4k
Sean Lilienfeld United States	14	1.1k 0.7×	1.2k 0.8×	547 0.5×	315 0.6×	568 1.2×	21	2.5k
Neal R. Cutler United States	40	1.8k 1.2×	1.5k 1.0×	1.1k 0.9×	831 1.5×	337 0.7×	164	5.8k
Hans Jörg Möbius Germany	16	911 0.6×	863 0.6×	934 0.8×	452 0.8×	406 0.9×	22	2.7k

Countries citing papers authored by Lawrence Friedhoff

Since Specialization

Citations

This map shows the geographic impact of Lawrence Friedhoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Friedhoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Friedhoff more than expected).

Fields of papers citing papers by Lawrence Friedhoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Friedhoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Friedhoff. The network helps show where Lawrence Friedhoff may publish in the future.

Co-authorship network of co-authors of Lawrence Friedhoff

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Friedhoff. A scholar is included among the top collaborators of Lawrence Friedhoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Friedhoff. Lawrence Friedhoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Friedhoff, Lawrence, et al.. (2019). Safety and Efficacy of First-in-Class mtROS scavenger SkQ1 for the Treatment of Dry Eye Disease: A Phase 3 Clinical Trial. Investigative Ophthalmology & Visual Science. 60(9). 6750–6750. 1 indexed citations

Wen, Warren, et al.. (2017). A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations (P6.088). Neurology. 88(16_supplement). 1 indexed citations

Lombardo, Ilise, et al.. (2017). Intepirdine (RVT-101), a 5-HT6 Receptor Antagonist, as an Adjunct to Donepezil in Mild-to-Moderate Alzheimer's Disease: Efficacy on Activities of Daily Living Domains. American Journal of Geriatric Psychiatry. 25(3). S120–S121. 4 indexed citations

Authier, Simon, Michael V. Accardi, Mylène Pouliot, et al.. (2016). Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods. 81. 306–312. 7 indexed citations

Glue, Paul, Gavin Cape, Michelle Lockhart, et al.. (2016). Ascending Single‐Dose, Double‐Blind, Placebo‐Controlled Safety Study of Noribogaine in Opioid‐Dependent Patients. Clinical Pharmacology in Drug Development. 5(6). 460–468. 45 indexed citations

Lombardo, Ilise, Geetha Ramaswamy, Stephen C. Piscitelli, & Lawrence Friedhoff. (2015). DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study. Alzheimer s & Dementia. 11(7S_Part_7). 583 indexed citations breakdown →

Winblad, Bengt, Ezio Giacobini, Lutz Frölich, et al.. (2011). Phenserine Efficacy in Alzheimer's Disease. Journal of Alzheimer s Disease. 22(4). 1201–1208. 54 indexed citations

Davidson, Michael H., et al.. (2002). A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clinical Therapeutics. 24(1). 112–125. 32 indexed citations

Niecestro, Robert, et al.. (2002). Comparative Pharmacokinetics of Lovastatin Extended‐Release Tablets and Lovastatin Immediate‐Release Tablets in Humans. The Journal of Clinical Pharmacology. 42(2). 198–204. 23 indexed citations

10.

Lamson, Michael, et al.. (2002). Pharmacokinetics of lovastatin extended‐release dosage form (Lovastatin XL) in healthy volunteers. Biopharmaceutics & Drug Disposition. 23(4). 143–149. 9 indexed citations

11.

Friedhoff, Lawrence, et al.. (2001). Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (Aβ) peptide. The International Journal of Neuropsychopharmacology. 4(2). 127–30. 86 indexed citations

12.

Bunnell, Eugene, Melvyn Lynn, Kalim Habet, et al.. (2000). A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Critical Care Medicine. 28(8). 2713–2720. 69 indexed citations

13.

Burns, Alistair, Martin N. Rossor, Jane Hecker, et al.. (1999). The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial<sup>1</sup>. Dementia and Geriatric Cognitive Disorders. 10(3). 237–244. 481 indexed citations

14.

Rogers, Samantha & Lawrence Friedhoff. (1997). 5-12-21 Donepezil provides long-term clinical benefits for patients with Alzheimer's disease (AD). Journal of the Neurological Sciences. 150. S296–S296. 7 indexed citations

15.

Bunnell, Eugene, Alex Neumann, Melvyn Lynn, et al.. (1995). E5531, AN ENDOTOXIN ANTAGONIST, BLOCKS THE HYPERDYNAMIC AND DEPRESSANT CARDIOVASCULAR EFFECTS OF ENDOTOXIN IN HEALTHY SUBJECTS. Critical Care Medicine. 23(Supplement). A151–A151. 6 indexed citations

16.

Glazer, William M., Lawrence Friedhoff, S. Marder, & Wendy J. Brown. (1992). The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection. Schizophrenia Research. 8(2). 111–117. 3 indexed citations

17.

Reed, Michael D., Stephen C. Aronoff, Robert C. Stern, et al.. (1986). Single‐dose pharmacokinetics of aztreonam in children with cystic fibrosis. Pediatric Pulmonology. 2(5). 282–286. 12 indexed citations

18.

MacLeod, Catherine, et al.. (1986). Aztreonam penetration into synovial fluid and bone. Antimicrobial Agents and Chemotherapy. 29(4). 710–712. 11 indexed citations

19.

Madsen, Paul O., et al.. (1984). Aztreonam concentrations in human prostatic tissue. Antimicrobial Agents and Chemotherapy. 26(1). 20–21. 16 indexed citations

20.

Friedhoff, Lawrence & B. J. Berne. (1976). Irreversible thermodynamic analysis of electrophoretic light scattering experiments. Biopolymers. 15(1). 21–28. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact